Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells
Methotrexate (MTX) is used in first-line treatment of primary central nervous system lymphoma (PCNSL), but most cases result in relapse-acquired resistance to MTX. However, only few studies have reported on internal changes and chemotherapies in PCNSL.
In this study, we generated two MTX-resistant PCNSL cell lines, designated MTX-HKBML and MTX-TK, in addition to a MTX-resistant Burkitt lymphoma cell line, designated MTX-RAJI. We examined gene expression changes and drug sensitivity to a proteasome inhibitor, bortezomib, in these cells.
Cytotoxic tests revealed that the 50% inhibitory concentration for MTX in MTX-HKBML is markedly higher than that in the other two cell lines. Expression of the genes in MTX and folate metabolisms, including gamma-glutamyl hydrolase and dihydrofolate reductase, are upregulated in both MTX-HKBML and MTX-TK, whereas the gene expression of folylpolyglutamate synthetase, thymidylate synthase, and methylenetetrahydrofolate dehydrogenase 1 were upregulated and downregulated in MTX-HKBML and MTX-TK, respectively, on the other hand, bortezomib sensitivity was observed in MTX-TK, as compared with control TK, but not in MTX-HKBML.
These results indicate the cell-type-specific changes downstream of metabolic pathways for MTX and folate, bortezomib sensitivity, and purine and pyrimidine syntheses, in each PCNSL cell line. The MTX-resistant lymphoma cell lines established may be useful for in vitro relapse models for MTX and development of salvage chemotherapy and drug discovery.
KeywordsPrimary central nervous system lymphoma Methotrexate Bortezomib Folate metabolism Purine and pyrimidine syntheses
The study was supported by the MEXT KAKENHI Grant numbers 16H05441, 16K10766, and 18K09001.
AH and RY designed the experiments. AH and YT performed the experiments. AH, YT, and RY analyzed data. AH, YT, and RY wrote the manuscript.
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of financial and non-financial interest exists.
- 6.Morris PG, Correa DD, Yahalom J et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971–3979CrossRefGoogle Scholar
- 20.Ribrag V, Gisselbrecht C, Haioun C et al (2009) Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 115:4540–4546CrossRefGoogle Scholar
- 29.Allegra CJ, Chabner BA, Drake JC et al (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720–9726Google Scholar
- 31.Göker E, Kheradpour A, Waltham M et al (1995) Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia 9:274–276Google Scholar
- 32.Matherly LH, Taub JW, Ravindranath Y et al (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 85:500–509Google Scholar
- 35.Romaguera JE, Wang M, Feng L et al (2018) Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer 124:2561–2569CrossRefGoogle Scholar
- 41.Wang W, Swenson S, Cho HY et al (2019) Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models. J Neurosurg 15:1–9Google Scholar